ICCC Relative Valuation
ICCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ICCC is overvalued; if below, it's undervalued.
Historical Valuation
ImmuCell Corp (ICCC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -60.29. The fair price of ImmuCell Corp (ICCC) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.47
Fair
-47.36
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ImmuCell Corp. (ICCC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-74.30
EV/EBIT
ImmuCell Corp. (ICCC) has a current EV/EBIT of -74.30. The 5-year average EV/EBIT is -77.84. The thresholds are as follows: Strongly Undervalued below -105.99, Undervalued between -105.99 and -91.92, Fairly Valued between -63.77 and -91.92, Overvalued between -63.77 and -49.69, and Strongly Overvalued above -49.69. The current Forward EV/EBIT of -74.30 falls within the Historic Trend Line -Fairly Valued range.
2.85
PS
ImmuCell Corp. (ICCC) has a current PS of 2.85. The 5-year average PS is 3.16. The thresholds are as follows: Strongly Undervalued below 1.39, Undervalued between 1.39 and 2.27, Fairly Valued between 4.05 and 2.27, Overvalued between 4.05 and 4.94, and Strongly Overvalued above 4.94. The current Forward PS of 2.85 falls within the Historic Trend Line -Fairly Valued range.
22.44
P/OCF
ImmuCell Corp. (ICCC) has a current P/OCF of 22.44. The 5-year average P/OCF is 24.90. The thresholds are as follows: Strongly Undervalued below 10.93, Undervalued between 10.93 and 17.91, Fairly Valued between 31.89 and 17.91, Overvalued between 31.89 and 38.87, and Strongly Overvalued above 38.87. The current Forward P/OCF of 22.44 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
ImmuCell Corp. (ICCC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
ImmuCell Corp (ICCC) has a current Price-to-Book (P/B) ratio of 1.59. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately 1.39% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about -11.35% higher. ImmuCell Corp (ICCC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.93%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.71% , the current FCF yield is about -100.00% lower.
1.58
P/B
Median3y
1.57
Median5y
1.80
1.51
FCF Yield
Median3y
-8.93
Median5y
-6.71
Competitors Valuation Multiple
The average P/S ratio for ICCC's competitors is 0.00, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -8.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ICCC increased by 1.17% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.75 to 20.18.
The secondary factor is the Revenue Growth, contributed -8.41%to the performance.
Overall, the performance of ICCC in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is ImmuCell Corp (ICCC) currently overvalued or undervalued?
What is ImmuCell Corp (ICCC) fair value?
How does ICCC's valuation metrics compare to the industry average?
What is the current P/B ratio for ImmuCell Corp (ICCC) as of Dec 05 2025?
What is the current FCF Yield for ImmuCell Corp (ICCC) as of Dec 05 2025?
What is the current Forward P/E ratio for ImmuCell Corp (ICCC) as of Dec 05 2025?